Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

First Albany Upgrades Myogen

Myogen (MYOG) reported 60 cents second-quarter loss per share, vs. 50 cents loss a year ago. First Albany upgraded the stock to strong buy.

Analyst Lucy Lu says that with upcoming catalysts, she believes the current risk/reward on Myogen is very attractive. She says while she views ambrisentan drug as Myogen's fundamental valuation driver, she believes darusentan has now become a free option with substantial upside. She notes she assumes an ambrisentan approval and commercialization in 2008.

Lu raised $28.2 million 2008 ambrisentan U.S. sales estimate to $31.5 million, 2009 estimate to $133.4 million from $68.6 million, and 2010 estimate to $257.3 million from $119.2 million.

She raised her $8 price target to $18; her NPV indicates ambrisentan is worth $17 a shrare, and darusentan is worth $11 share.

blog comments powered by Disqus